Trending

ASH17

CAR-Ts dominated the agenda at ASH 2017

CAR-Ts dominated the agenda at ASH 2017

The American Society for Hematology congress was dominated by CAR-T therapies – their potential new uses, how to

X

CAR-Ts dominated the agenda at ASH 2017

https://pharmaphorum.com/views-analysis-oncology/car-ts-dominated-agenda-ash-2017/

Roche/AbbVie combination could raise standards in CLL

Roche/AbbVie combination could raise standards in CLL

A leukaemia combination therapy could help revive the fortunes of Roche and AbbVie, following late-stage trial results showing

X

Roche/AbbVie combination could raise standards in CLL

https://pharmaphorum.com/news/rocheabbvie-combination-better-chemo-cll/

Gilead goes full throttle on CAR-Ts with $567m acquisition

Gilead goes full throttle on CAR-Ts with $567m acquisition

Gilead hopes CDL technology will create therapies targeting solid tumours

X

Gilead goes full throttle on CAR-Ts with $567m acquisition

https://pharmaphorum.com/news/gilead-buy-cell-design-labs-567-million/

‘Cure for hemophilia within reach’ as BioMarin and Spark gene therapies shine

‘Cure for hemophilia within reach’ as BioMarin and Spark gene therapies shine

While clinicians attending the American Society of Hematology meeting in Atlanta this weekend were anticipating a flurry of

X

‘Cure for hemophilia within reach’ as BioMarin and Spark gene therapies shine

https://pharmaphorum.com/news/cure-hemophilia-within-reach-biomarin-spark-gene-therapies-shine/

Spark and Pfizer’s gene therapy wows in haemophilia B

Spark and Pfizer’s gene therapy wows in haemophilia B

Gene therapy company Spark Therapeutics has published data showing its one-time treatment can almost entirely eliminate bleeds in

X

Spark and Pfizer’s gene therapy wows in haemophilia B

https://pharmaphorum.com/news/spark-pfizers-gene-therapy-wows-haemophilia-b/

ASH 2017: CAR-T therapy and beyond

ASH 2017: CAR-T therapy and beyond

As the American Society of Hematology’s 2017 congress approaches, there’s plenty to be excited about – not just

X

ASH 2017: CAR-T therapy and beyond

https://pharmaphorum.com/views-analysis-oncology/ash-2017-car-t-therapy-beyond/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com